Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

755 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Billon E, Dalban C, Oudard S, Chevreau C, Laguerre B, Barthélémy P, Borchiellini D, Geoffrois L, Negrier S, Joly F, Thiery-Vuillemin A, Gross-Goupil M, Rolland F, Priou F, Mahammedi H, Tantot F, Escudier B, Chabaud S, Albiges L, Gravis G. Billon E, et al. Among authors: joly f. Eur Urol Oncol. 2024 Aug;7(4):742-750. doi: 10.1016/j.euo.2023.09.009. Epub 2023 Oct 7. Eur Urol Oncol. 2024. PMID: 37813745 Clinical Trial.
Sleep macro- and microstructure in breast cancer survivors.
Perrier J, Duivon M, Clochon P, Rehel S, Doidy F, Grellard JM, Segura-Djezzar C, Geffrelot J, Emile G, Allouache D, Levy C, Polvent S, Viader F, Eustache F, Joly F, Giffard B. Perrier J, et al. Among authors: joly f. Sci Rep. 2022 Feb 15;12(1):2557. doi: 10.1038/s41598-022-06664-z. Sci Rep. 2022. PMID: 35169245 Free PMC article.
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.
Eymard JC, Priou F, Zannetti A, Ravaud A, Lepillé D, Kerbrat P, Gomez P, Paule B, Genet D, Hérait P, Ecstein-Fraïssé E, Joly F. Eymard JC, et al. Among authors: joly f. Ann Oncol. 2007 Jun;18(6):1064-70. doi: 10.1093/annonc/mdm083. Epub 2007 Apr 13. Ann Oncol. 2007. PMID: 17434899 Free article. Clinical Trial.
[Case report of kidney cancer from JOUM 2010].
Neuzillet Y, Guy L, Long JA, Zini L, Chevreau C, Duclos B, Escudier B, Gimel P, Joly F, Lang H, Mejean A, Oudard S, Roumeguere T. Neuzillet Y, et al. Among authors: joly f. Prog Urol. 2011 Mar;21 Suppl 2:S27-33. doi: 10.1016/S1166-7087(11)70006-9. Prog Urol. 2011. PMID: 21397824 French.
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Fléchon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Zanetta S, Fargeot P, Priou F, Droz JP, Culine S. Fléchon A, et al. Among authors: joly f. Ann Oncol. 2011 Nov;22(11):2476-2481. doi: 10.1093/annonc/mdr004. Epub 2011 Mar 24. Ann Oncol. 2011. PMID: 21436186 Free article. Clinical Trial.
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Heudel PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, Roche-Forestier S, Meunier J, Foa C, You B, Priou F, Tazi Y, Floquet A, Selle F, Berton-Rigaud D, Lesoin A, Kalbacher E, Lortholary A, Favier L, Treilleux I, Ray-Coquard I. Heudel PE, et al. Among authors: joly f. Br J Cancer. 2017 Jan;116(3):303-309. doi: 10.1038/bjc.2016.430. Epub 2017 Jan 10. Br J Cancer. 2017. PMID: 28072765 Free PMC article. Clinical Trial.
755 results